Oncternal Therapeutics to Report Very first Quarter 2021 Fiscal Success and Give Enterprise Update
SAN DIEGO, April 29, 2021 (World NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a medical-phase biopharmaceutical business centered on the growth of novel oncology therapies, right now declared that it will report initial quarter 2021 economical benefits soon after the U.S. financial marketplaces close on Thursday, Might 6, 2021. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to talk about the Company’s economical success and supply a extensive business enterprise update.
The live webcast of the get in touch with will be accessible on the internet by using a link from the investor relations web site of the Company’s internet site at www.oncternal.com, and the get in touch with will be archived there for at least 30 times.
About Oncternal Therapeutics
Oncternal Therapeutics is a medical-stage biopharmaceutical corporation targeted on the growth of novel oncology therapies for the therapy of cancers with critical unmet clinical want. Oncternal focuses drug growth on promising still untapped biological pathways implicated in cancer era or progression. The scientific pipeline contains cirmtuzumab, an investigational monoclonal antibody created to inhibit the ROR1 pathway, a style I tyrosine kinase-like orphan receptor, that is currently being evaluated in a Stage 1/2 scientific demo in blend with ibrutinib for the treatment method of people with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Period 1b medical trial in mix with paclitaxel for the remedy of women with HER2-adverse metastatic or regionally state-of-the-art, unresectable breast most cancers. The medical pipeline also contains TK216, an investigational qualified small-molecule inhibitor of the ETS spouse and children of oncoproteins, that is staying evaluated in a Phase 1 clinical demo for clients with Ewing sarcoma alone and in mix with vincristine chemotherapy. In addition, Oncternal has a program using the cirmtuzumab antibody backbone to develop a Vehicle-T treatment that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and good tumors. More information and facts is offered at www.oncternal.com.
Oncternal Contacts:
Business Get hold of
Richard Vincent
858-434-1113
[email protected]
Investor Get hold of
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
[email protected]
Resource: Oncternal Therapeutics, Inc.